Phase 1 Trial of Intratumoral MQ710 Alone or With Pembrolizumab for Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating the safety and appropriate dosing of MQ710 in people with advanced solid tumor cancers that have returned, spread, or worsened after standard treatments, or for whom no standard treatments are available. This phase 1 study aims to find the highest dose of MQ710 that causes few or mild side effects. The trial includes various types of solid tumors such as cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, and others. Participants will receive MQ710 injected directly into their tumors, either alone or combined with pembrolizumab, which is administered intravenously every three weeks at a standard dose. The study involves a dose escalation group using a 33 scheme to find the safe dose range, followed by a dose expansion group to further evaluate the chosen doses of MQ710 alone or with pembrolizumab. Treatment schedules and doses are carefully monitored throughout the trial. During the study, participants will undergo tumor biopsies, assessments of tumor response, and safety monitoring for up to two years after treatment. Researchers will review side effects, laboratory tests, and overall health status to evaluate the safety of MQ710. Participants must comply with study procedures, including regular visits, tumor evaluations, and use of contraception if applicable. The study duration may vary depending on individual response and study phase completion.

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer